Home

Metastatic adenoid cystic carcinoma

Adenoid cystic carcinoma (ACC) is a rare malignant tumor of the salivary glands, with higher frequency in the submandibular gland, a prolonged clinical course, and poor long‐term survival. It tends to metastasize to lungs, bone, liver, brain, and rarely to skin BACKGROUNDAdenoid cystic carcinoma (ACC) is a rare malignancy arising in salivary glands and other sites, characterized by high rates of relapse and distant spread. Recurrent/metastatic (R/M) ACCs are generally incurable, due to a lack of active systemic therapies. To improve outcomes, deeper unders Adenoid cystic carcinoma (ACC) is a rare cancer with high potential for recurrence and metastasis. Efficacy of current treatment options, particularly for advanced disease, is very limited. Recent whole genome and exome sequencing has dramatically improved our understanding of ACC pathogenesis Background: We examined the assumption in conventional teaching about metastatic adenoid cystic carcinoma (ACC) being an indolent type of disease

Adenoid cystic carcinoma tends to invade the nerves and cause distant hematogenous metastasis (3), which is usually observed in the lungs (4), whereas renal metastasis is commonly observed in lung, breast and other cancers (5). Renal metastasis of a submandibular gland adenoid cystic carcinoma is rare Adenoid cystic carcinomas (ACCs) are rare tumors, and mostly arise from salivary gland, especially minor salivary glands.1They can also arise in various sites of the head and neck including the tracheobronchial tree and even in sites outside the head and neck, such as breast, uterine cervix, prostate, and the skin.2They have paradoxical behaviors Advanced disease refers recurrent tumors at the primary (original) site or distant metastases. Physicians do not have a clear standard of care or approved drugs to recommend to ACC patients with advanced disease, so treatment plans are highly individualized and patient preferences often drive the final decision Purpose: We evaluated the safety and efficacy of pembrolizumab (pembro) ± radiation therapy (RT) in a phase 2 study among patients with progressive, metastatic adenoid cystic carcinoma (ACC). Methods and materials: Eligible patients had metastatic ACC with progression within the last year and ≥1 measurable lesion. Patients were randomized to pembro alone or with RT to 30 Gy in 5 fractions. Doctors treat adenoid cystic carcinoma as a chronic condition. Remote metastases can occur a decade or more after initial treatment of the primary tumor, with the most common metastatic locations being the lung, bone, and viscera

Adenoid Cystic Carcinoma: Stages Approved by the Cancer.Net Editorial Board , 08/2020 ON THIS PAGE: You will learn about how doctors describe an AdCC tumor's growth or spread General Discussion Adenoid cystic carcinoma (ACC) is a relatively rare form of cancer that most commonly develops in the salivary glands or other regions of the head and neck. ACC can occur in other parts of the body, such as the breast, skin, cervix in females, prostate gland in males, and various other areas Abstract Background: Adenoid cystic carcinoma (ACC) is a rare malignancy of epithelial origin. It involves a variety of histologic types and often has distant metastasis. ACC metastasis to the liver is rare and usually involves spread to other organs

no clinical study on epidermal growth factor receptor tyrosine kinase inhibitors has been systematically conducted in adenoid cystic carcinoma. We design this phase II study EGFR TKIs in adenoid cystic carcinoma to evaluate its efficacy in this disease. The histologic appearance of adenoid cystic. Adenoid cystic carcinoma (ACC) is an uncommon form of malignant neoplasm that arises within secretory glands, most commonly the major and minor salivary glands of the head and neck. Other sites of origin include the trachea, lacrimal gland, breast, skin, and vulva. This neoplasm is defined by its distinctive histologic appearance The large majority of information regarding chemotherapy for metastatic adenoid cystic carcinoma is derived from experience with advanced salivary gland tumors. In these tumors, several traditional.. Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone. Caballero M, E Sosa A, Tagliapietra A, Grau JJ Head Neck 2013 Feb;35(2):E52-4 Recurrent or metastatic adenoid cystic carcinoma (R/M ACC) is a malignant neoplasm of predominantly salivary gland origin for which effective therapies are lacking. We conducted a phase II trial evaluating the multitargeted tyrosine kinase inhibitor lenvatinib in patients with R/M ACC

Adenoid cystic carcinoma is a rare malignant parotid tumor. Metastasis can occur even a decade or more after initial treatment of the primary 5581. Background: Adenoid cystic carcinomas [ACC] originate from a variety of sites, most commonly from the salivary glands. While generally not curable once metastatic, the disease course may be protracted and indolent. The precise role of systemic therapy [ST] in the management of advanced ACC is controversial

Adenoid cystic carcinoma of submandibular gland metastatic

Statistics adapted from the Adenoid Cystic Carcinoma Research Foundation, the National Organization for Rare Disorders, and the Oral Cancer Foundation (sources accessed January 2021). The next section in this guide is Risk Factors. It explains what factors may increase the chance of developing AdCC Commonly ACC metastases have a high tendency to appear in both lungs and to spread into more than one lobe. A less invasive treatment (RFA, Brachytherapy, Cryoablation, SBRT) should be considered to maintain as much healthy lung tissue as possible. Adenoid Cystic Carcinoma Organization International PO Box 936, Lake Forest, CA 92630 [email. 1. Ann Oncol. 2012 Jun;23(6):1562-70. doi: 10.1093/annonc/mdr522. Epub 2011 Nov 11. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC Adenoid cystic carcinoma is a rare type of cancer that can exist in many different body sites. This tumor most often occurs in the salivary glands, but it can also be found in many anatomic sites, including the breast, lacrimal gland, lung, brain, bartholin gland, trachea, and the paranasal sinuses

Tubular/Cribriform Carcinoma | Basicmedical Key

Distant metastasis of adenoid cystic carcinoma (ACC) is most commonly identified in the lung, but risk factors are still on debate Adenoid Cystic Carcinoma. This is Cancer.Net's Guide to Adenoid Cystic Carcinoma. Use the menu below to choose the Introduction section to get started. Or, you can choose another section to learn more about a specific question you have. Each guide is reviewed by experts on the Cancer.Net Editorial Board, which is composed of medical, surgical.

Video: Genetic hallmarks of recurrent/metastatic adenoid cystic

Adenoid cystic carcinoma: current therapy and potential

Differences in patterns of survival in metastatic adenoid

Adenoid cystic carcinoma (ACC) is a rare tumor, usually arising in the salivary gland, accounting for 1% of all head and neck cancers. ACC may have a long-term poor prognosis, as about 40% of radically treated patients will recur locoregionally and up to 60% will develop distant metastasis 6022 Background: Recurrent/metastatic adenoid cystic carcinoma (R/M ACC) is a malignant neoplasm of salivary gland origin with no standard treatment. The majority of ACCs are characterized by MYB over-expression which correlates to upregulation of several genes, including lenvatinib-relevant targets such as vascular endothelial growth factor A, the receptor tyrosine kinase KIT and fibroblast. The incidence of neck metastases in adenoid cystic carcinoma of the head and neck is considered low and reported incidence range from 0 to 18%. If tumors of the submaxillary gland are considered separately, the incidence of neck metastases reported ranges from 0 to loo%, with a pooled incidence of 34%, signifi 6026 Background: There is no specific therapy, including targeted agents, has consistently improved clinical outcomes in recurrent/metastatic adenoid cystic carcinoma of the head and neck (ACCHN). Recently, anti-angiogenic targeted therapy represents a potential effective strategy. We conducted a single-arm, phase II trial to evaluate apatinib, a small-molecule inhibitor of VEGFR-2, in ACCHN. ACC (Adenoid Cystic Carcinoma) is a rare and unique form of cancer that is known to be unpredictable in nature, with a typical growth pattern of being slow and gradual, but over time can be progressive, insidious and relentless. There are some general tendencies, such as the propensity for it to spread into surrounding nerve tissue or.

Imaging appearance of a singular metastatic adenoid cystic

Adenoid cystic carcinoma (ACC) is a rare salivary gland malignant neoplasm. Clinically it represents as an indolent yet a persistent lesion, which shows propensity for late distant metastases, involving vital tissues often leading to the death of the patient. Its innoceous clinical presentation remains a diagnostic challenge 6082 Background: Adenoid cystic carcinoma (ACC) is a salivary gland malignancy characterized by a high rate of distant recurrence. Systemic therapy has generally failed to produce durable benefit. Radiation (RT) is used for localized disease and as directed treatment for metastases. Here, we report the safety and efficacy of pembrolizumab (pembro) administered with or without hypofractionated. Adenoid cystic cancer (ACC) is the most common SGC histotype observed in metastatic subjects (60%) and distant metastases are the principal cause of failure, being diagnosed in 25-55% of the patients. First-line treatment is palliative chemotherapy that is typically not associated with any benefit neither in response rate nor in outcome Adenoid cystic carcinoma is a rare malignant tumor arising from exocrine glands such as the major and minor salivary glands of the paranasal sinuses or the external auditory canal. Although multiple retrospective clinical studies of ACC have been reported to date, clinical questions, such as 1) long-term prognosis beyond 20 years, 2) usefulness and suitability for treatment of therapeutic.

Adenoid cystic carcinoma (ACC) is a rare malignant tumor of the salivary glands, with higher frequency in the submandibular gland, a prolonged clinical course, and poor long‐term survival.It tends to metastasize to lungs, bone, liver, brain, and rarely to skin. Comprehensive skin examination and appropriate follow‐up is recommended, since cutaneous metastasis represents disease progression. However, postoperative immunohistochemical analysis showed that the tumor was a metastatic adenoid cystic carcinoma. During the secondary pulmonary relapse, although the tumor was correctly diagnosed as a metastatic adenoid cystic carcinoma by intraoperative examination, it again mimicked primary lung adenocarcinoma

Metastasectomy for Hepatic Metastases from Adenoid Cystic

Advanced Disease - Adenoid Cystic Carcinoma Research

  1. The objective of this study was to evaluate the efficacy and safety of dovitinib in patients with adenoid cystic carcinoma (ACC). METHODS. ACC patients with documented disease progression within the past 12 months were eligible
  2. Adenoid cystic carcinoma metastatic to the dura: report of two cases Amrit Kaur1, Mark R. Harrigan2, Paul E. MeKeever3 and Donald A. Ross2 1University of Michigan Medical School, 2Section of Neurosurgery, Department of Surgery, 3Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI, US
  3. Dedifferentiated adenoid cystic carcinomas are a recently defined, rare variant of adenoid cystic carcinomas characterized histologically by two components: conventional low-grade adenoid cystic.
  4. or salivary gland that metastasized to the colon 19 years after the primary tumor resection, with literature.
  5. Adenoid Cystic Carcinoma: Types of Treatment Approved by the Cancer.Net Editorial Board , 08/2020 ON THIS PAGE: You will learn about the different types of treatments doctors use for people with AdCC
  6. Background. Adenoid cystic carcinoma (ACC) accounts for approximately 10% of all neoplasms of the salivary glands. Late distant metastases and local recurrences are responsible for a rather low long‐term survival rate
  7. Adenoid cystic carcinoma is a rare type of cancer that can exist in many different body sites. This tumor most often occurs in the salivary glands, but it can also be found in many anatomic sites, including the breast, lacrimal gland, lung, brain, bartholin gland, trachea, and the paranasal sinuses.. It is the third-most common malignant salivary gland tumor overall (after mucoepidermoid.

A Randomized Phase 2 Study of Pembrolizumab With or

  1. Research is growing with Adenoid Cystic Carcinoma, the life expectancy is changing as research expands and technology improves. Posted May 19, 2017 by Carmenita 2650 Treatment for ACC and other cancers are always changing, and the life expectancy changes with those improvements
  2. Non-ACC Cohort (Cohort 2) only: Patients must have pathologically or cytologically confirmed salivary gland cancer of any histology (except for adenoid cystic carcinoma that is enrolled into cohort 1). Patients must have recurrent and/or metastatic disease not amenable to other curative intent therapy
  3. PRESENTED ON: October 18-21, 2020. INTRODUCTION: Adenoid cystic carcinoma of the salivary gland is a rare carcinoma of the head and neck, accounting for approximately 1% of all malignancies involving the head and neck. We present a case of metastatic adenoid cystic carcinoma of the salivary gland. CASE PRESENTATION: A 33-year-old female patient.
  4. Primary cutaneous adenoid cystic carcinoma (PCACC) is a rare skin cancer thought to originate from sweat ducts.. What are adenoid cystic carcinomas?. PCACC is part of a group of tumours called adenoid cystic carcinomas. They share similar features under the microscope (see pathology of adenoid cystic carcinoma) but have distinct differences in clinical behaviour and prognosis
  5. Histologically confirmed recurrent or metastatic adenoid cystic carcinoma not amenable to curative intent surgery or radiotherapy Measurable disease per RECIST 1.1 Evidence of disease progression within 6 months of study enrollment or worsening disease-related symptom
  6. Adenoid cystic carcinoma (ACC) is a relatively rare tumour of the salivary glands, accounting for approximately 5%-10% of all salivary gland tumours. An important feature of ACCs is the long clinical course with a high rate of distant metastases. The preferential sites of metastases are the lung and bone, followed by the brain and liver
  7. al computed tomography scan performed in the context.

Adenoid Cystic Carcinoma Symptoms and Treatment UPM

Adenoid Cystic Carcinoma: Stages Cancer

  1. In conclusion, adenoid cystic carcinoma is a rare form of vulvar cancer. These tumors are slow-growing but are locally aggressive and have a high recurrence rate. Early diagnosis by a biopsy to rule out underlying carcinoma in patients with a mass in the Bartholin's gland is recommended
  2. Background: Adenoid cystic carcinoma (ACC) is a relatively indolent cancer, for which the major cause of death is distant metastases. The median survival time of patients with distant metastases of ACC is approximately 20 months. Although the liver is not the most common site of secondary ACC, effective treatment of liver metastases could improve patient survival
  3. Adenoid cystic carcinoma (ACC) is a rare malignant tumor arising mostly in the head and neck region that commonly involves the salivary glands [].The standard treatment for primary ACC is surgery in most patients [].Approximately 40-60% of patients with ACC develop distant metastases at ≥10 years after diagnosis [2, 3].The most frequent site of distant metastases is the lung [], and.
  4. Background. Adenoid cystic carcinoma (ACC) accounts for approximately 10%-15% of all salivary gland tumours and 1% of head and neck cancers.1 ACC is generally characterised by its lengthy course, indolent behaviour, delayed and silent metastasis.1 About 35%-50% of patients with this carcinoma develop distant metastases, usually to the lungs and less commonly to the liver and the bone.2 ACC.
  5. The Prognosis of Adenoid Cystic Carcinoma is largely dependent on the stage and the location of the disease. A patient with locally recurrent Adenoid Cystic Carcinoma has a high rate of survival and respond better to the treatment. However, if the tumour has spread all across the body then it is difficult to control Adenoid Cystic Carcinoma.
  6. AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 Understanding the Burden of ACC Through the Eyes of Patients A Study of PRT543 in Participants With.
  7. Salivary adenoid cystic carcinoma (SACC) is a peculiar malignant tumor, characterized by its slow but inexorable growth, with a high incidence of lung metastasis and poor prognosis. Here, we show the upregulated expression of EGFR ligand epiregulin in a subset of SACC cells correlates with lung metastasis and unfavorable outcome in patients.

Adenoid Cystic Carcinoma - NORD (National Organization for

Purpose: Vorinostat is a histone deacetylase inhibitor (HDACi). Based on a confirmed partial response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior phase 1 trial, we initiated this phase 2 trial Introduction. Adenoid cystic carcinoma is a malignant neoplasm that arises within the secretory glands, most commonly in the salivary glands of the head and neck ().Salivary adenoid cystic carcinoma (SACC), which arises from ductal, myoepithelial, and basal cells, comprises approximately 25% of the malignant tumors in the major salivary glands and approximately 50% of those in the minor glands ()

Liver metastasis from adenoid cystic carcinoma of the

PURPOSE: The role of chemotherapy in adenoid cystic carcinoma (ACC) is controversial because ACC is usually stable without chemotherapy and lack of randomized trials. Here, we conducted the first randomized trial to evaluate the efficacy of axitinib as compared to observation in ACC. PATIENTS AND METHODS: In this multicenter, prospective phase II trial, we enrolled patients with recurrent or. Preclinical results for AL101 monotherapy in patient-derived xenograft models of adenoid cystic carcinoma were presented at the 2019 American Association for Cancer Research Annual Meeting. 2 The agent had previously been explored in a phase I trial of patients with locally advanced or metastatic solid tumors and had demonstrated a partial. FIGURE 2 High-grade transformation of adenoid cystic carcinoma on histology. A, Low-power view showing two distinct carcinomatous components: conventional adenoid cystic carcinoma (left portion) and high-grade carcinoma with a predominantly solid growth pattern, forming irregular and confluent tumor nests (right portion) (H&E stain, ×100)

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic

  1. Adenoid cystic carcinoma (ACC) is a rare malignancy arising in salivary glands and other sites, characterized by high rates of relapse and distant spread. Recurrent/metastatic (R/M) ACCs are generally incurable, due to a lack of active systemic therapies
  2. Metastases from tracheal adenoid cystic carcinoma. A 32-year-old female never smoker presented with dyspnoea and stridor. CT thorax showed a polypoidal mass obstructing the trachea. Bronchoscopy revealed a circumferential nodular tumour 4 cm from the vocal cords, removed using electrosurgical snare and thereby re-establishing trachea patency.
  3. Adenoid cystic carcinoma (ACC) most often develops in salivary glands, accounting for approximately 1% of head and neck malignancies. 1 It grows slowly but is prone to recurrence, and distant metastasis. 2 Recurrent or metastatic ACC of the head and neck (R/MACCHN) represents one of the most intractable tumors, for which the progression-free.

Adenoid Cystic Carcinoma: Latest Research. Approved by the Cancer.Net Editorial Board, 08/2020. ON THIS PAGE: You will read about the scientific research being done to learn more about this type of cancer and how to treat it. Use the menu to see other pages. in the control of metastatic or locally recurrent AdCC Full Title A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects with Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin Purpose The purpose of this study is to assess the safety and effectiveness of the investigational drug rivoceranib in patients with recurrent or metastatic adenoid cystic carcinoma that cannot. Adenoid Cystic Carcinoma (AdCC) is a very rare form of cancer which can occur in various parts of the body. The neck and head are the most common sites of occurrence of this type of cancer. AdCC usually affects the major as well as the minor salivary glands. The distinctive histologic appearance is the main characteristic of this type of neoplasm The multitargeted tyrosine kinase inhibitor lenvatinib had antitumor activity in patients with recurrent or metastatic adenoid cystic carcinoma (ACC), but required active monitoring and management.

Adenoid Cystic Carcinoma - The Oral Cancer Foundatio

  1. Adenoid cystic carcinoma is a rare form of cancer that usually affects the salivary glands in the mouth and throat. It typically manifests as a painless tumor in the mouth that can eventually spread to the lungs or other parts of the body. As the tumor grows, it can cause numbness in the tongue or face muscles, a sore throat, fatigue, and weakness
  2. Adenoid Cystic Carcinoma Organization International partners with ACCRF to educate and support ACC patients.ACCOI moderates a Facebook group that enables a community of caring patients, caregivers, family members and friends to share insights and ideas on treatment plans, side effects and other issues of concern. ACCOI also moderates Facebook groups for subsets of ACC patients, such as those.
  3. Adenoid cystic carcinoma (ACC) is an uncommon tumor, constituting approximately 10% of all head and neck tumors. Classically, ACC has been described as a tumor with indolent, but persistent and recurrent, growth and late onset of metastases, leading eventually to death

Adenoid cystic carcinomas mostly occur in the salivary glands. Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs. Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur. Lymph node metastases are unusual; hematogenous tumor spread is characteristic Introduction: Laryngeal adenoid cystic carcinoma (LACC) is an extremely rare malignant neoplasm. The etiology of LACC remains unknown, and it is characterized by multiple recurrences, slow progression, and late distant metastasis Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. Lots of conflicts of interest [Adenoid cystic carcinoma of the head and neck: a retrospective series of 169 cases] Mean follow up was about 5 years (58 months). Radiotherapy did not impact survival. The value of MYB as a prognostic marker for adenoid cystic carcinoma: Meta-analysi

Oral Pathology Seattle - Oral Pathology Biopsy ServicePathology Outlines - WHO classification

ACC (Adenoid Cystic Carcinoma) is a rare and unique form of cancer that is known to be unpredictable in nature, with a typical growth pattern of being slow and gradual, but over time can be progressive, insidious and relentless. Metastatic spread to the lungs is a common occurrence in a large number of ACC patients and it can also spread to. A 32-year-old female never smoker presented with dyspnoea and stridor. CT thorax showed a polypoidal mass obstructing the trachea. Bronchoscopy revealed a circumferential nodular tumour 4 cm from the vocal cords, removed using electrosurgical snare and thereby re-establishing trachea patency (figure 1A,B). Histology showed adenoid cystic carcinoma (ACC)

Introduction:Adenoid cystic carcinoma (ACC) is a malignant neoplasm that arises within secretory glands. It rarely occurs in the lacrimal gland. Kidney metastases are very rare.Case presentation:We.. (C) The postoperative pathology study demonstrated metastatic adenoid cystic carcinoma. Discussion ACC of the lung is a relatively rare lung cancer arising from the bronchial glands and accounting for about 0.04-0.2% of all lung cancers. 1 ACC has been considered to be low-grade malignancy duo to its low growing and prolonged clinical course. [email protected] 28 Argonaut, Suite 150 Aliso Viejo, CA 92656 Phone: (+1) 949-248-RARE (7273 Primary sinonasal adenoid cystic carcinoma presenting with skin metastases-genomic profile and expression of the MYB-NFIB fusion biomarker. Histopathology: 24410806: 2009 Dec 30: Ha, El-Naggar: Mitochondrial mutations in adenoid cystic carcinoma of the salivary glands. PLoS One: 20041111: 2017 Dec 28: Weigelt, Reis-Filh Adenoid cystic carcinoma (ACC) of the lacrimal gland is a rarely encountered orbital tumor. It invades intracranially more frequently than carcinomas of other glands in the head and neck. A 61-year-old man underwent right orbital exenteration for a tumor in the supraorbital region. He had lost all records and presented to us with a diffuse.

Multiple Bone Metastases With Adenoid Cystic Carcinoma

1 Introduction. Adenoid cystic carcinoma (ACC) is a rare malignant tumour first reported in 1856 as 'cylindroma' by Theodor Bilroth (1829-1894) .Surgery is the treatment of choice, although ACC is known for its propensity to late and multiple distant metastases, with the lung being the most commonly involved organ .Because of the relative rarity of the disease, however, and because of. Ferrarotto R, Wirth LJ, Muzaffar J, et al. ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC.

Cancer Awareness Clip Art - ClipartsAtypical Cystic Parotid Gland Acinic Cell Carcinoma in a Child

Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus Callosum. Garber ST, Khoury L, Bell D, Schomer DF, Janku F, McCutcheon IE. World Neurosurg, 95:621.e13-621.e19, 10 Aug 2016 Cited by: 1. The records of 71 patients with adenoid cystic carcinoma of the salivary glands were reviewed to determine the dose response relationships for this aggressive tumor. Local control after treatment was determined for all patients and analyzed with respect to extent of surgery and dose of radiation. Of 70 patients who were available for evaluation. Adenoid cystic breast carcinoma is a rare form of breast cancer, which is named after its microscopic appearance [5, 6].It is a non-aggressive type of breast carcinoma with a very good chance of full recovery and it has a low propensity for metastasis [7, 8].Only two cases of ACC with brain metastases and two other cases with kidney metastases were reported in the literature [9,10,11,12]; the. Adenoid cystic carcinoma tends to invade the nerves and cause distant hematogenous metastasis , which is usually observed in the lungs , whereas renal metastasis is commonly observed in lung, breast and other cancers . Renal metastasis of a submandibular gland adenoid cystic carcinoma is rare